From a recent Pharmion SEC Filing:
"The Company made significant progress in the third quarter advancing its product pipeline. Pharmion initiated several clinical studies across its portfolio, including a Phase 3 study in small cell lung cancer for Amrubicin, Phase 1 and Phase 2 studies in solid tumors and CLL for MGCD0103, opened centers and began enrolling patients in the dose escalation study for oral Azacitidine, and commenced our research program targeting sirtuin inhibitors. Research and development (R&D) expenses totaled $29.1 million for the third quarter of 2007, compared to $16.7 million for the third quarter of 2006. For the nine months ended September 30, 2007, research and development costs totaled $72.0 million, compared to $50.2 million for the nine-month period ended September 30, 2006."
It is very interesting to see that a large cap pharma is just now initiating its research into Sirtuins. Sirtris has over 140 patents in this area and with this intellectual property is attempting to position itself as the gatekeeper of Sirtuin technology. These patents could prove to be especially valuable as this field of science progresses.
Thursday, December 20, 2007
Subscribe to:
Post Comments (Atom)
2 comments:
Did you notice that they are working on Sirtuin inhibitors, not sirtuin activators like SIRT is working on. Maybe Sirtris has locked up too many of the Sirtuin activators and others, like Elixir Pharmaceuticals, are stuck with inhibitors. Any thoughts?
Yes I did notice and Pharmion is still at least two years away:
"Pharmion expects to file an initial Investigational New Drug (IND) application within the next 24 to 30 months. (Aug 2007)"
I can only speculate that all of SIRT's intellectual property related to the activation of sirtuins effectively makes it the gatekeeper of this technology. Could be a very lucrative position to be in once progress is shown in clinical trials.
Post a Comment